Last reviewed · How we verify
NCT03557398
Efficacy and Safety of HYDEAL-D Vaginal Pessaries Application on the Treatment of Vaginal Atrophy in Post-menopause Women
NA trial testing Hydeal-D vaginal pessaries in Vulvovaginal Atrophy in 40 participants. Completed in 29 May 2018.
29 May 2018
Quick facts
| Lead sponsor | Fidia Farmaceutici s.p.a. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 29 November 2017 |
| Primary completion | 29 May 2018 |
| Estimated completion | 29 May 2018 |
| Sites | 2 locations across Slovakia |
Drugs / interventions tested
- Hydeal-D vaginal pessaries
Conditions studied
- Vulvovaginal Atrophy — all drugs for Vulvovaginal Atrophy →
Sponsor
Fidia Farmaceutici s.p.a. — full company profile →
Who can join
Adults 45 to 75, female only, with Vulvovaginal Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy and safety of hyaluronic acid derivative based vaginal pessaries for the treatment of symptoms of vulvo-vaginal atrophy in post-menopausal women.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?
Nappi RE, Martella S, Albani F, Cassani C, et al · · 2022 · cited 15× · PMID 36011183 · DOI 10.3390/healthcare10081528
Verify or expand the search:
- PubMed search for NCT03557398
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vulvovaginal Atrophy
Currently open trials in the same condition.
- NCT05562518 — GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therap · Phase 4 · active not recruiting
Other Fidia Farmaceutici s.p.a. trials
Trials by the same sponsor.
- NCT06190028 — Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Gl · NA · terminated
- NCT06108999 — Management of Acute and Chronic Wounds With Hyaluronic Acid · NA · recruiting
- NCT06062771 — Efficacy and Safety of the Use of Ophthalmic Viscosurgical Devices (OVD) FIDIAL PLUS vs IAL®-F During Cataract Surgery · NA · completed
- NCT06103812 — Evaluate Performance and Safety of Hyalo4 Skin in Acute and Chronic Wounds · unknown
- NCT04757038 — An Open Label, Randomized-controlled Trial to Assess Efficacy Safety of HYALODISC With Physical Exercise Program · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03557398 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fidia Farmaceutici s.p.a.
- Last refreshed: 15 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03557398.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing